Zevra shareholders elect directors, ratify auditor; board declassification fails

ZEVRA THERAPEUTICS, INC.

Douglas W. Calder elected as Class II director with 25.8M for, 8.0M withheld (12.6M broker non-votes).
Corey Watton elected as Class II director with 29.9M for, 3.8M withheld (12.6M broker non-votes).
Ratification of Ernst & Young as auditor for FY 2026 approved: 45.9M for, 234.8K against, 144.6K abstain.
Proposal to declassify board failed; received 32.6M for vs. 1.1M against, needed >66-2/3% of outstanding shares.

item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 20, 2026 (File No. 001-36913) (the “Proxy Statement”): (1) to elect Douglas W. Calder and Corey Watton to the Company’s Board as Class II directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified (“Proposal 1”)

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Proposal 2 — Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 45,947,281 234,753 144,582 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ZEVRA THERAPEUTICS, INC. shareholders rejected Approve an amendment to the Restated Certificate of Incorporation to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting be elected on an annual basis at the 2026-06-04 meeting.

Proposal: charter amendment
Outcome: failed
Meeting: 2026-06-04

Exact text from the filing

Proposal 3 — Vote to Approve an Amendment to the Charter to Declassify the Board: For Against Abstain Broker Non-Votes 32,557,653 1,145,079 16,950 12,606,934

View on SEC.gov

995 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001434647-26-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.